Juno Therapeutics’ stock surges in debut
December 19, 2014 at 13:11 PM EST
Juno Therapeutics stock surges in debut above IPO price, valuing the cancer drug developer at more than $3 billion.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|